Keywords: ahp, rapamune, improves, 6-month, graft, survival, clinical
AHP's Rapamune Improves 6-Month Graft Survival
Article | 16 July 1998
Two clinical trials of American Home Products' new immunosuppressantRapamune (sirolimus; formerly rapamycin) have found that the drug is effective in ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
